שווי נכסים נקי Creative Medical Technology Holdings, Inc. (CELZ)

Creative Medical Technology (CELZ) is emerging as an innovator in tissue regeneration, developing the AmnioStem system to combat urological diseases through immunomodulation. This chart illustrates the asset's price action, where the key metric stands at 0.01. The company is currently scaling trials for impotence and stroke treatments across US centers. The business relies on proprietary patents to create safe alternatives to surgical intervention for joint injuries.

To determine fundamental stability, it is essential for investors to evaluate the book capitalization of Creative Medical Technology (CELZ) as the difference between total assets and liabilities, reflecting the actual value of net equity. Monitoring the dynamics of book capitalization allows for the correlation of the growth of the asset base of Creative Medical Technology (CELZ) with achievements in cell therapy development and patents, confirming that the business capitalization is backed by tangible scientific and technological assets.